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Mitral regurgitation frequently coexists in patients with severe aortic stenosis. Patients
with moderate to severe mitral regurgitation at the time of transcatheter aortic valve
replacement are at increased risk of future adverse events. Whether concomitant mitral
regurgitation is independently associated with worse outcomes after TAVR remains
a matter of debate. The optimal therapeutic strategy in these patients—TAVR with
evidence-based heart failure therapy, combined TAVR and transcatheter mitral valve
intervention, or staged transcatheter therapies—is ill-defined, and guideline-based
recommendations in patients at increased risk for open heart surgery are lacking. Hence,
a thorough evaluation of the aortic and mitral valve anatomy and function, along with
an in-depth assessment of the patients’ baseline risk profile, provides the basis for an
individualized treatment approach. The aim of this review is therefore to give an overview
of the current literature on mitral regurgitation in TAVR, focusing on different diagnostic
and therapeutic strategies and optimal clinical decision making.
Keywords: transcatheter aortic vave replacement, mitral valve insufficiency, mitral valve repair, aortic stenosis,
aortic valve, mitral valve
INTRODUCTION
Concomitant mitral regurgitation is frequently observed in patients with severe aortic
stenosis (1–3). About 20% of patients undergoing transcatheter (TAVR) or surgical (SAVR)
aortic valve replacement for severe aortic stenosis have concomitant more than mild mitral
regurgitation (1–3). Whether concomitant mitral regurgitation is independently associated with
worse outcomes after aortic valve replacement is uncertain (4). A thorough evaluation of the
aortic and mitral valve anatomy and function is important in these patients and mainly based on
transthoracic and transesophageal echocardiography. An in-depth understanding of the underlying
pathophysiological mechanism provides the basis for an individualized treatment approach and
optimal procedural planning. Emerging minimally invasive surgical and transcatheter treatment
strategies offer novel, less-invasive therapeutic options for combined, staged or hybrid procedures
when severe aortic stenosis and mitral regurgitation do coexist, particularly in elderly patients,
obviating the need for open heart surgery (5). The treatment of first choice in these patients,
however, remains a matter of debate, and guideline-based recommendations are lacking.
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The aim of this review is therefore to give an overview of
the current literature on mitral regurgitation in TAVR, with
particular focus on the different diagnostic and therapeutic
strategies available and on the clinical decision-making process
in patients at increased surgical risk.
ASSESSMENT OF MITRAL
REGURGITATION IN PATIENTS WITH
SEVERE AORTIC STENOSIS
In mitral regurgitation, besides the grading of the regurgitation
severity, identification of the underlying etiology, particularly the
distinction between primary and secondary mitral regurgitation,
is of great importance to guide therapeutic management.
The assessment of the mitral valve apparatus and the type
of dysfunction is mainly based on transthoracic and/or
transesophageal echocardiography with multimodality imaging
used in specific situations (6, 7). Although transthoracic
echocardiography is diagnostic in most cases, transesophageal
echocardiography complements the assessment when
transthoracic image quality is suboptimal and further diagnostic
refinement is required (6, 7). Transesophageal echocardiography
not only provides additional important information on the
etiology of the disease, but also helps to determine the feasibility
of dedicated transcatheter mitral valve procedures. Three-
dimensional (3D) echocardiography facilitates anatomic and
functional interpretation, particularly in patients with complex
valvular pathologies (6, 8, 9).
Mitral regurgitation may either be primary/degenerative
due to abnormalities of the valvular apparatus itself such as
mitral valve prolapse, flail leaflets, and chordal rupture, or
secondary/functional due to restricted leaflets, mostly caused
by left ventricular dilatation and dysfunction in ischemic
cardiomyopathy and chronic pressure overload related to aortic
stenosis (10). Annular dilatation and left atrial enlargement
causing insufficient leaflet closure, e. g., in patients with long-
standing atrial fibrillation, may also be an underlying cause.
Mixed forms exist when both pathologies overlap. As the mitral
valvular apparatus is often calcified in patients with degenerative
aortic stenosis, pure secondary mitral regurgitation is unlikely in
this context (4).
An integrated approach using qualitative, semi-quantitative,
and quantitative echocardiographic parameters allows for a
comprehensive assessment of mitral regurgitation (9, 11, 12).
Color flow imaging is the most common way to detect mitral
regurgitation, with quantification based on the integration of
further measures such as vena contracta width, PISA radius,
regurgitation volume and effective regurgitant orifice area
(EROA) (6). The evaluation of mitral regurgitation in aortic
stenosis may, however, be challenging as jet velocity may be
increased due to high left ventricular pressures (4). On the other
hand, concomitant mitral regurgitation impacts on transvalvular
gradient and flow in severe aortic stenosis, which may hamper
echocardiographic assessment (13).
A thorough echocardiographic evaluation of the mitral
valve apparatus is needed to determine the feasibility of
TABLE 1 | Favorable echocardiographic criteria for transcatheter edge-to-edge
mitral valve repair with the MitraClip® system.
Favorable echocardiographic
criteria
Unfavorable echocardiographic
criteria
Regurgitation located in the
midportion of the valve
Rheumatic valve disease
Absence of leaflet calcifications in the
grasping area
Leaflet perforation or clefts
Mitral valve area >4 cm2 Mitral stenosis
Posterior leaflet length ≥10mm Posterior leaflet length <7mm
Flail gap <10mm and flail width
<15mm
Coaptation depth <11mm and
coaptation length >2mm
Adapted from Wunderlich and Siegel (17).
transcatheter mitral valve interventions (14–16). Unfavorable
echocardiographic criteria for percutaneous edge-to-edge mitral
valve repair include severe leaflet calcifications in the grasping
area, rheumatic leaflet thickening, perforated leaflets or clefts,
and amobile length of the posteriormitral valve leaflet of<7mm,
along with insufficient mechanical coaptation in functional
(coaptation depth >11mm, coaptation length <2mm) and
excessive flail gap in degenerative disease (fail gap >10mm and
flail width >15mm, Table 1) (15–17). A pre-procedural mitral
valve area of >4 cm2 is recommended in order to reduce the
risk of post-procedural mitral valve stenosis (17). Advanced
imaging modalities such as multidetector computed tomography
(MDCT) complement the assessment of these patients. Besides
the evaluation of the aorto-iliacal axis in TAVR patients, MDCT
provides important information on the mitral valve apparatus,
particularly on annular dimensions, the extent and localization of
calcifications, and the spacial relationship to adjacent structures
(16, 18, 19).
IMPACT OF MITRAL REGURGITATION ON
OUTCOMES IN PATIENTS WITH SEVERE
AORTIC STENOSIS
Patients with aortic stenosis and coexisting moderate to severe
mitral regurgitation are known to have a worse clinical risk
profile as compared to those without, which is also reflected by
higher surgical risk scores (20, 21). They are older, have a higher
prevalence of atrial fibrillation and prior myocardial infarction,
and poorer left ventricular systolic function (LVEF) (20–
22). Whether concomitant mitral regurgitation independently
affects outcomes in patients undergoing AVR remains an
ongoing matter of debate, particularly whether secondary mitral
regurgitation is related with outcomes irrespective of left
ventricular dysfunction. While some studies did not observe
any association between the presence of mitral regurgitation
and adverse events after SAVR (23, 24), others demonstrated
an increased risk of mortality, heart failure, and need for
future mitral valve repair/replacement when mitral regurgitation
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was treated medically (2, 25, 26). While in some studies,
mitral regurgitation did not emerge as independent predictor of
mortality after TAVR (2, 20, 27), the majority of studies clearly
pointed toward an increased risk of mortality when coexistent
moderate to severe mitral regurgitation was present at the time
of TAVR (28–34). In a meta-analysis including 4,839 TAVR
patients, all-cause mortality was significantly higher in patients
with moderate to severe mitral regurgitation (29). Similarly,
in a multicenter registry including 1,007 patients undergoing
TAVRwith the CoreValve Revalving System, 1-yearmortality was
significantly higher in patients with moderate or severe mitral
regurgitation as compared to those without (31). Differences in
the gradingmethodology of mitral regurgitation which was based
on qualitative echocardiographic measures in most studies, along
with varying inclusion criteria, mainly regarding the etiology
and severity of mitral regurgitation, may hamper comparisons
among studies. Most interestingly, in the PARTNER (Placement
of AoRTic TraNscathetER Valve) trial, patients with moderate to
severe mitral regurgitation seemed to experience an even greater
benefit from TAVR than those without, as reflected in a smaller
number needed to treat to prevent a fatality (35).
TREATMENT STRATEGIES IN PATIENTS
WITH SEVERE AORTIC STENOSIS AND
MITRAL REGURGITATION
As double valve surgery is associated with an increased mortality
as compared to SAVR or combined SAVR and coronary artery
bypass grafting (36), transcatheter therapeutic options represent
promising less-invasive treatment alternatives to open heart
surgery in high-risk patients. Despite the high prevalence of
concomitant mitral regurgitation in patients with severe aortic
stenosis and the associated substantial morbidity and mortality,
randomized trials investigating different therapeutic strategies
are lacking. Whether concomitant mitral regurgitation should
be treated medically or addressed in combined or staged
procedures is ill-defined, and optimal patient selection and
timing of interventions need to be determined. The evidence
in this field is mostly stemming from observational data and
case series, which precludes firm conclusions. Given the lack
of guideline-based recommendations, personalized treatment
strategies based on associated symptoms, the individual valvular
pathology, the comorbid burden, and the estimated procedural
risk are advocated (10). Irrespective of attempted surgical or
transcatheter approaches to mitral regurgitation, guideline-based
heart failure management is essential in these patients before
evaluating the regurgitation severity.
The Guideline-Based Heart Team Approach
All patients with severe symptomatic aortic stenosis and
concomitant mitral regurgitation, who are at increased surgical
risk, are evaluated by a multidisciplinary Heart Team to ensure
comprehensive risk stratification and optimal patient selection.
Besides technical aspects, associated symptoms, the burden of
comorbidities, patient’s life expectancy, patient’s frailty, and the
quality of life need to be taken into account to deliver best
quality of care (10). Thereby, a balanced decision on the optimal
treatment strategy is taken for each individual patient.
Guideline-based indications for mitral valve procedures are
summarized in Table 2. The distinction between primary and
secondary mitral regurgitation is emphasized in this context.
Although mitral valve repair/replacement is considered the
gold standard in patients with symptomatic severe mitral
regurgitation (10), benefits in those with secondary forms are
less clear as lack of survival benefit and an increased risk
of recurrence have been reported (37), finally resulting in
lower levels of evidence for treatment recommendations in
this patient subgroup. According to current guidelines of the
European Society of Cardiology (ESC) (10), intervention for
severe chronic primary mitral regurgitation is indicated in
symptomatic patients with preserved left ventricular ejection
fraction (LVEF >30%, class of recommendation I, level of
evidence B) with valve repair being the preferred treatment
approach. Surgery is further indicated in asymptomatic patients
with left ventricular dysfunction as mirrored by a reduced left
ventricular systolic function [LVEF ≤60%] or increased left
ventricular dimensions (left ventricular end-systolic diameter
≥45mm, class of recommendation I, level of evidence B),
and should be considered in patients with new onset of
atrial fibrillation or increased pulmonary pressures (systolic
pulmonary pressure ≥50 mmHg, class of recommendation IIa,
level of evidence B), and flail leaflet or significant left atrial
dilatation (class of recommendation IIa, level of evidence C)
(10). Percutaneous edge-to-edge repair may be considered by the
Heart Team for symptomatic patients at high surgical risk (class
of recommendation IIb, level of evidence C). Currently, there is
no indication to intervene for moderate mitral regurgitation.
In patients with severe secondary mitral regurgitation,
optimal guideline-recommended heart failure therapy, including
optimal medical therapy and coronary revascularization
or cardiac resynchronization as indicated, is of particular
importance (10, 38). For the treatment of severe secondary
mitral regurgitation, a class I recommendation for mitral valve
surgery with valve repair being the method of first choice exists in
patients undergoing coronary artery bypass graft surgery, when
LVEF is preserved (level of evidence C). In symptomatic patients
with reduced left ventricular systolic function (LVEF <30%),
surgery should be considered when coronary revascularization
is indicated (class of recommendation IIa, level of evidence C).
When there is no option for coronary revascularization, mitral
valve surgery may be considered in patients with preserved
LVEF and low surgical risk (class of recommendation IIb, level
of evidence C). A percutaneous edge-to-edge procedure may be
considered when echocardiographic criteria of eligibility are met
and surgical risk deemed prohibitive (class of recommendation
IIb, level of evidence C). Although transcatheter percutaneous
mitral valve procedures were shown to substantially reduce the
degree of mitral regurgitation, beneficially affect left ventricular
reverse remodeling, and significantly decrease the symptomatic
burden (15, 39–41), it remains uncertain whether survival
benefits are achieved. Emerging interventional procedures such
as transcatheter annuloplasty or transapical valve replacement
complement the therapeutic armamentarium for severe mitral
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TABLE 2 | Recommendations for the treatment of chronic mitral regurgitation according to the 2017 European Society of Cardiology (ESC) and European Association for
Cardio-Thoracic Surgery (EACTS) guidelines for the management of valvular heart disease.
Recommendations Class of recommendation Level of evidence
PRIMARY MITRAL REGURGITATION
Mitral valve repair is the treatment of choice when durable results are expected. I C
Mitral valve surgery is indicated in patients with severe symptomatic mitral
regurgitation and preserved left ventricular systolic function (LVEF >30%).
I B
Mitral valve surgery is indicated in asymptomatic patients with severe mitral
regurgitation and left ventricular dysfunction (LVEF ≤60% or LVESD ≥45mm).
I B
Mitral valve surgery should be considered in asymptomatic patients with atrial
fibrillation or pulmonary hypertension (systolic pulmonary pressure at rest >50
mmHg)
IIa B
Mitral valve surgery should be considered in asymptomatic patients with low surgical
risk, preserved left ventricular function (LVEF >60%) and LVESD between 40 and
44mm, when durable repair is likely and there is a flail leaflet or left atrial
dilatation (LAVI >60 ml/m2)
IIa C
Mitral valve repair should be considered in symptomatic patients with low surgical
risk and severe left ventricular dysfunction (LVEF <30% and/or LVESD >55mm)
refractory to optimal heart-failure therapy when successful repair is likely
IIa C
Mitral valve replacement may be considered in symptomatic patients with low
surgical risk and severe left ventricular dysfunction (LVEF <30% and/or LVESD
>55mm) refractory to optimal heart-failure therapy when likelihood of repair is low
IIb C
Percutaneous edge-to-edge repair may be considered by the Heart Team in
patients with symptomatic severe mitral regurgitation, who meet the
echocardiographic criteria of eligibility and are deemed at high or prohibitive
surgical risk
IIb C
SECONDARY MITRAL REGURGITATION
Mitral valve surgery is indicated in patients with severe mitral regurgitation
undergoing CABG
I C
Mitral valve surgery should be considered in patients with severe symptomatic
mitral regurgitation and left ventricular dysfunction (LVEF <30%) with an option for
coronary revascularization
IIa C
Mitral valve surgery may be considered in patients with low surgical risk, preserved
left ventricular systolic function (LVEF >30%) and severe symptomatic mitral
regurgitation refractory to optimal heart-failure therapy
IIb C
Percutaneous edge-to-edge repair may be considered in patients deemed at
high or prohibitive surgical risk with no option for coronary revascularization, who
have severe symptomatic mitral regurgitation refractory to optimal heart-failure
therapy and meet the echocardiographic criteria of eligibility
IIb C
Percutaneous edge-to-edge repair or valve surgery may be considered by the
Heart Team in patients deemed at high or prohibitive surgical risk with no option
for coronary revascularization and severe left ventricular dysfunction (LVEF
<30%), who have severe symptomatic mitral regurgitation refractory to optimal
heart-failure therapy and meet the echocardiographic criteria of eligibility
IIb C
Adapted from Baumgartner et al. (10). CABG, coronary artery bypass grafting; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic
diameter.
regurgitation in high risk patients. Experience with these
procedures is, however, still limited and guideline-based
recommendations lacking.
TAVR and Natural Course of Mitral
Regurgitation
Most studies report on a significant improvement of mitral
regurgitation after AVR, which has mostly been attributed
to reverse left ventricular remodeling and improved left
ventricular function. Indeed, in a meta-analysis including 8,927
patients undergoing TAVR, the severity of mitral regurgitation
significantly improved in about 60% of patients (42). In
the PARTNER trial, moderate to severe mitral regurgitation
was observed in 21% of SAVR and 20% of TAVR patients,
and improvement was reported in 69% of SAVR and 58%
of TAVR patients at 30 days (2). Similar results were
reported in other studies (32, 43, 44). These effects may be
particularly predominant in patients with secondary mitral
regurgitation as structural valve alterations obviously persist
after TAVR. A significant improvement in mitral regurgitation
severity is more likely to occur in patients without severe
pulmonary hypertension and atrial fibrillation (31) Interestingly,
acute improvement in mitral regurgitation has been reported
following TAVR and was related to immediate post-procedural
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changes in left ventricular hemodynamics and improved mitral
leaflet tethering (45). Whether the design of the implanted
transcatheter heart valve influences the post-procedural course
of mitral regurgitation needs to be delineated in future
studies. Observational studies point toward a greater degree of
reduction of mitral regurgitation in patients treated with balloon-
expandable as compared to self-expandable transcatheter heart
valves (28).
Combined TAVR and Transcatheter Mitral
Valve Procedure
In comparison to a single valve procedure, surgical double valve
replacement/repair is associated with increased morbidity and
mortality (36, 46). Indeed, mortality rates of about 10% have
been reported for double valve aortic and mitral surgery as
compared to 3% for isolated SAVR (36). Over the last decades,
transcatheter techniques have evolved and offer less-invasive
treatment alternatives to double valve surgery in patients deemed
at high or prohibitive surgical risk. Transcatheter mitral valve
replacement (TMVR) offers a less invasive treatment alternative
to redo cardiac surgery, particularly in high-risk patients
with degenerated mitral bioprostheses and failed annuloplasty
rings (47). Clinical experience with bivalvular transcatheter
procedures, however, is still limited (48, 49). The success of
a combined approach with transcatheter mitral valve repair
performed at the time of TAVR has been reported in several
studies (50, 51). Different transcatheter mitral valve repair
technologies may be used in this context such as the MitraClip R©
device (Abbott Vascular Inc., Menlo Park, CA, USA), the Carillon
Mitral Contour System R© (Cardiac Dimensions, Kirkland, WA,
USA), and the Cardioband R© (Valtech, Edwards Lifescience Corp,
Irvine, CA, USA) (52) An overview of current devices for
transcatheter mitral valve repair is provided in Table 3.
The most advanced percutaneous mitral valve repair system is
the MitraClip R© device which allows for introducing a V-shaped
clip on the mitral valve leaflets via a transseptal approach under
transesophageal echocardiographic and fluoroscopic guidance
(Figure 1). Thereby, a double or multiple orifice is created (14–
16). High procedural success rates of percutaneous edge-to-edge
mitral valve repair have not only been reported for primary,
but also secondary mitral regurgitation (41, 53), and safety and
efficacy was also demonstrated in patients who did not meet
the key echocardiographic eligibility criteria as determined by
the EVEREST (Endovascular Valve Edge-to-Edge Repair) studies
(54).
Percutaneous indirect mitral annuloplasty was developed
to improve leaflet coaptation by reducing mitral annular
dimensions using dedicated transcatheter devices such as
the Carillon Mitral Contour System R©. The Carillon Mitral
Contour System R© consists of anchors at both ends, which
are connected by a curved nitinol ribbon connector. The
device is implanted within the coronary sinus to reduce the
severity of mitral regurgitation by annular placation (14, 55).
Safety and feasibility of the procedure, along with clinical
benefits in terms of heart failure symptoms, quality of life, and
exercise tolerance have been shown for patients with dilated
cardiomyopathy and functional mitral regurgitation in different
studies such as the AMADEUS (the CarillonMitral Annuloplasty
Device European Union Study) and the TITAN (Transcatheter
Implantation of Carillon Mitral Annuloplasty Device) trials (40,
55). The direct annuloplasty Cardioband R© system represents
a similar interventional transseptal approach for the treatment
of secondary mitral regurgitation (56) The annuloplasty band
is implanted around the posterior mitral annulus, aiming at
reducing mitral regurgitation by decreasing septolateral annular
dimensions.
Besides minimally invasive surgical valve repair or
replacement, TMVR has emerged as less-invasive treatment
alternative for patients deemed at high or prohibitive surgical
risk, with several prostheses already introduced in clinical
practice (57–59). Although feasibility and safety of valve-in-
valve, valve-in-ring, and valve-in-native ring procedures have
been demonstrated for transcatheter heart valve implantation in
the mitral position (60), future randomized studies are needed
to determine the role of TMVR in patients with severe mitral
regurgitation.
TAVR and Staged Transcatheter Mitral
Valve Procedure
As significant improvements in mitral regurgitation severity have
been observed after AVR (26, 43, 44), a staged approach may
be favored over a combined procedure with the aortic valve
being addressed first and the mitral valve treated only in patients
who remain symptomatic in spite of successful TAVR (50, 61).
Patients with prior AVR undergoing transcatheter mitral valve
repair, however, represent a complex patient subgroup with a
high comorbid burden at increased risk of adverse events. One-
year survival in these patients was reported to be below 50%
(62).
Given the lack of randomized comparisons between surgical
and transcatheter double valve interventions vs. medical
management of mitral regurgitation in the context of severe
aortic stenosis, evidence-based recommendations on patient
selection and optimal timing of interventions cannot be made.
For predominantly secondary mitral regurgitation, when no
major structural mitral valve defects exist, a staged approach
may be reasonable to tailor mitral interventions to patients
with persistent symptomatic mitral regurgitation, who may
benefit most. Bivalvular interventions may be advocated when
concomitant predominantly primary mitral regurgitation is
present.
Based on our experience, we strongly advocate a stepwise
approach in this high-risk patient population, with TAVR being
performed first and percutaneous mitral valve repair considered
by the Heart Team only when severe mitral regurgitation
persists after TAVR. A close clinical and echocardiographic
follow-up of these patients following TAVR is mandatory, with
functional tests used when grading of mitral regurgitation is
challenging.
Cost-Effectiveness of Transcatheter Valve
Procedures
Although procedural costs of TAVR exceed those of SAVR,
cost-effectiveness of TAVR in patients at increased surgical
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TABLE 3 | Overview of devices for transcatheter mitral valve repair.
Device Principle Characteristics
MitraClip (Abbot Vascular) Edge-to-edge repair - V-shaped clip is placed on the mitral valve leaflets via transseptal approach
- Device produces a double mitral valve orifice
Pascal (Edwards Lifescience) Edge-to-edge repair - Central spacer with two paddles is placed on the mitral valve leaflets via
transseptal approach
- Device produces a double mitral valve orifice
Carillon (Cardiac Dimensions) Indirect annuloplasty - Anchors at both ends are connected by a curved nitinol ribbon connector
- Device is implanted within the coronary sinus to decrease annular
dimensions
Cardioband (Valtech, Edwards Lifescience) Direct annuloplasty - Annuloplasty band implanted around the posterior mitral annulus
- Device decreases septolateral annular dimensions
Mitralign (Mitralign Inc.) Direct annuloplasty - Pledget delivery system with retrograde aortic access
- Reduction of the annular circumference is achieved by two pairs of
pledgets placed at opposite sites of the annulus and producing tissue
plication
NeoChord DS 1000 (NeoChord Inc.) Chordal repair - Artificial chord-based system implanted via transapical access, secured to
the leaflet and anchored to the left ventricular apex
Harpoon TSD-5 (Edwards Lifescience) Chordal repair - Artificial chord-based system implanted via transapical access, secured to
the leaflet and anchored to the left ventricular apex
FIGURE 1 | Pre- and post-procedural transesophageal echocardiography in a patient undergoing staged transcatheter aortic valve replacement (TAVR) and
edge-to-edge mitral valve repair with the MitraClip® system. (A) Transesophageal color Doppler echocardiography at baseline (three-chamber view) showing severe
aortic stenosis and concomitant severe mitral regurgitation. (B) Transesophageal echocardiography at baseline (aortic valve short-axis view) showing severe aortic
stenosis. (C) Two-dimensional transesophageal color Doppler echocardiography (three chamber view) showing persistent severe mitral regurgitation following TAVR.
(D) Two-dimensional transesophageal echocardiography (three chamber view) following TAVR. (E) Two-dimensional transesophageal color Doppler echocardiography
(three-chamber view) during staged percutaneous edge-to-edge mitral valve repair with the MitraClip® system (grasping). (F) Two-dimensional transesophageal
echocardiography (three-chamber view) during staged percutaneous edge-to-edge mitral valve repair with the MitraClip® system (grasping).
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risk has been demonstrated when shorter hospital stay and
reduced need for post-acute rehabilitation services are taken
into account, particularly when a transfemoral access is suitable
(63–66). In heart failure patients with moderate-to-severe mitral
regurgitation, therapy with the MitraClip R© device was shown to
be cost-effective compared to medical management alone (67).
Direct economic comparisons between different transcatheter
mitral valve repair systems and mitral valve surgery are, however,
lacking. A staged approach with TAVR performed first and
percutaneous mitral valve repair tailored to patients who do not
experience any improvement in mitral regurgitation following
TAVR seems to be cost-effective, as thereby the number of mitral
valve interventions is reduced in comparison to simultaneous
procedures.
CONCLUSION
Risk assessment and optimal patient selection, along with a
personalized treatment approach defined by the Heart Team,
is important to ensure best patient care in symptomatic
aortic stenosis and concomitant mitral regurgitation. Given
the heterogeneity and complexity of mitral valve disease in
these high-risk patients, individualized treatment concepts
are needed. Although the feasibility and safety of bivalvular
transcatheter procedures have been demonstrated, the treatment
of first choice—TAVR only, staged TAVR and transcatheter
mitral valve procedures, or combined bivalvular transcatheter
therapy vs. minimally-invasive surgical treatment—remains
to be determined. Randomized trials investigating benefits
of mitral valve procedures vs. guideline-based heart
failure therapy in TAVR patients with concomitant mitral
regurgitation will help to define optimal treatment approaches.
Refinements of transcatheter mitral valve concepts including
the combination of different approaches will probably enter
clinical practice in near future and further improve patient
outcomes.
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